Last reviewed · How we verify
Mesenchymal stromal cell therapy
At a glance
| Generic name | Mesenchymal stromal cell therapy |
|---|---|
| Also known as | Methylprednisolone, Mesenchymal stem cells, BMMSCs= Bone Marrow Mesenchymal Stem Cells |
| Sponsor | R.P.Herrmann |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Safety and Efficacy of Mesenchymal Stromal Cells (Amimestrocel ) in Diabetic Kidney Disease (PHASE2)
- Autologous SVF Therapy for Type 2 Diabetes (NA)
- Double-blind, Randomized, Controlled Clinical Trial to Assess Efficacy of MSC in Patients With COVID-19 ARDS (PHASE2)
- Pilot Study of Radiation-Induced Xerostomia Treatment With Allogeneic Mesenchymal Stromal Stem Cells (PHASE1)
- Umbilical Cord Mesenchymal Stem Cells as Adjuvant Therapy in Group E COPD Patients (PHASE2)
- Combination of Conditioned Medium and Umbilical Cord-Mesenchymal Stem Cells Therapy for Acute Stroke Infarct (PHASE1, PHASE2)
- Bone Marrow Versus Adipose Tissue as a Cell Source for Infiltrative Treatment of Knee Osteoarthritis (NA)
- Study Transplanting Bone Marrow Cells Into Salivary Glands to Treat Dry Mouth Caused by Radiation Therapy (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Mesenchymal stromal cell therapy CI brief — competitive landscape report
- Mesenchymal stromal cell therapy updates RSS · CI watch RSS
- R.P.Herrmann portfolio CI